连续血糖监测
医学
人工胰腺
1型糖尿病
平均差
糖尿病
显著性差异
血糖自我监测
2型糖尿病
内科学
内分泌学
置信区间
作者
Rabab Z. Jafri,Courtney A. Balliro,Firas H. El-Khatib,Michele Maheno,Mallory Hillard,Alexander J. O'donovan,Rajendranath Selagamsetty,Hui Zheng,Edward R. Damiano,Steven J. Russell
出处
期刊:Diabetes Technology & Therapeutics
[Mary Ann Liebert]
日期:2020-11-01
卷期号:22 (11): 846-852
被引量:56
标识
DOI:10.1089/dia.2019.0449
摘要
Background: There is a dearth of comparative accuracy studies of continuous glucose monitoring (CGM) devices in the home-use setting, and none with the Eversense implantable CGM. Methods: We evaluated the accuracy of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense during a 6-week free-living home-use bionic pancreas study involving 23 subjects with type 1 diabetes who wore all three devices concurrently. The primary outcome was the mean absolute relative difference (MARD) between CGM readings and point-of-care (POC) plasma-glucose (PG) values obtained approximately twice daily by the subjects. We compared PG values with CGM readings when available from all three CGMs in the 5 min preceding the PG values (n = 829 sets). Since the Libre Pro records readings every 15 min, we also did a two-way comparison between the G5 and the Eversense with a higher number of comparisons (n = 2277 sets). Results: All three CGM systems produced higher average MARDs than during in-clinic studies. However, since all three CGM systems were worn by the same individuals and used the same meter for comparator PG measurements, we could directly compare their performances. In the three-way comparison, Eversense achieved the lowest nominal MARD (14.8%) followed by Dexcom G5 (16.3%) and Libre Pro (18.0%) (Eversense vs. Libre Pro P = 0.004, other comparisons P = NS). There was a statistically significant difference (P = 0.008) in the two-way comparison of the MARDs for Eversense (15.1%) and G5 (16.9%). Conclusions: The point accuracy of the Eversense was better than two other CGMs when compared with POC PG values.
科研通智能强力驱动
Strongly Powered by AbleSci AI